224 related articles for article (PubMed ID: 20413348)
1. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Relling MV; Altman RB; Goetz MP; Evans WE
Lancet Oncol; 2010 Jun; 11(6):507-9. PubMed ID: 20413348
[No Abstract] [Full Text] [Related]
2. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
4. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetics in pediatrics].
Jacqz-Aigrain E
Arch Pediatr; 2001 May; 8 Suppl 2():342s-344s. PubMed ID: 11394110
[No Abstract] [Full Text] [Related]
6. Practical considerations for pharmacogenetic testing.
Wedlund PJ
MLO Med Lab Obs; 2001 Sep; 33(9):16-21, 23; quiz 24-5. PubMed ID: 11569125
[No Abstract] [Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
8. [Research advances in pharmacogenomics of mercaptopurine].
Chen XX; Shen SH
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Sep; 19(9):1027-1033. PubMed ID: 28899477
[TBL] [Abstract][Full Text] [Related]
9. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.
Hoffman JM; Haidar CE; Wilkinson MR; Crews KR; Baker DK; Kornegay NM; Yang W; Pui CH; Reiss UM; Gaur AH; Howard SC; Evans WE; Broeckel U; Relling MV
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):45-55. PubMed ID: 24619595
[TBL] [Abstract][Full Text] [Related]
10. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetics].
Hach I; Kirch W
Praxis (Bern 1994); 2008 Oct; 97(21):1127-9. PubMed ID: 18951351
[No Abstract] [Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.
Teh LK; Bertilsson L
Drug Metab Pharmacokinet; 2012; 27(1):55-67. PubMed ID: 22185816
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects.
Leeder JS; Gaedigk A
Pharmacogenomics; 2014 Jun; 15(8):1055-8. PubMed ID: 25084197
[No Abstract] [Full Text] [Related]
15. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
Bell GC; Caudle KE; Whirl-Carrillo M; Gordon RJ; Hikino K; Prows CA; Gaedigk A; Agundez J; Sadhasivam S; Klein TE; Schwab M
Clin Pharmacol Ther; 2017 Aug; 102(2):213-218. PubMed ID: 28002639
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data.
Kruger B; Shamley D; Soko ND; Dandara C
Clin Transl Sci; 2024 Mar; 17(3):e13761. PubMed ID: 38476074
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Chan CWH; Law BMH; So WKW; Chow KM; Waye MMY
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1395-1404. PubMed ID: 32270286
[TBL] [Abstract][Full Text] [Related]
18. Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
Pharmacogenomics; 2016 Dec; 17(18):1967-1969. PubMed ID: 27883289
[No Abstract] [Full Text] [Related]
19. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
20. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.
Suzuki H; Fukushima H; Suzuki R; Hosaka S; Yamaki Y; Kobayashi C; Sakai A; Imagawa K; Iwabuchi A; Yoshimi A; Nakao T; Kato K; Tsuchida M; Kiyokawa N; Koike K; Noguchi E; Fukushima T; Sumazaki R
J Hum Genet; 2016 Sep; 61(9):797-801. PubMed ID: 27193222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
